Roivant eyes Lisraya label expansion on Phase III uveitis win
Analysts are currently heralding the potential of Roivant's Lisraya to act as a competitor for the standard of care title in NIU.
The post Roivant eyes Lisraya label expansion on Phase III uveitis win appeared first on Clinical Trials Arena .